Autopsy report · NCT04150562

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

“This study was terminated early due to manufacturer withdrawal of support (study medication) due to lack of enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 1 year 4 months before it stopped.
• 2 participants enrolled.
• Results were posted on the registry 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Clear-Cell Renal Carcinoma

Interventions

rhIL-15; Avelumab

Participants

2

Sites

1

Countries

United States

Trials that died the same way

• One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
  “The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.” (89% match in meaning)
• Alvimopan Use in Polytraumatized Patients
  “This study was terminated due to failure to enroll, a low volume of patients met criteria.” (84% match in meaning)
• A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
  “The study was terminated due to low enrollment.” (84% match in meaning)
• Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease
  “This study was terminated due to low participant enrollment.” (84% match in meaning)
• MIRACLE EF Clinical Study
  “The study was terminated early due to low enrollment.” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.